Lenalidomid Basics

Lenalidomide, the active ingredient in Lenalidomid Basics, is an immunomodulatory drug (IMiD) presented as an oral dosage form for systemic use. It is employed in the treatment of certain blood cancers, notably multiple myeloma and myelodysplastic syndromes, and is prescribed for adult patients under specialist supervision.

GNH USA supplies Lenalidomid Basics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support safe import and distribution.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders. - Multiple myeloma (relapsed/refractory): Improves progression‑free survival and overall response when combined with dexamethasone. - Multiple myeloma (newly diagnosed, in combination): Enhances depth of response as part of frontline therapy. - Myelodysplastic syndromes with del(5q): Reduces transfusion dependence and improves cytopenias.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels causing bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Constipation: difficulty passing stool. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic toxicity: elevated liver enzymes or liver injury. - Severe neutropenia: profound infection risk requiring hospitalization. - Cardiac events: rare arrhythmias or myocardial infarction.

Before initiating therapy, clinicians should assess baseline health status and monitor patients regularly. - Dose adjustment: required in renal impairment to avoid accumulation. - Blood monitoring: perform routine complete blood counts to detect cytopenias early. - Thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. - Pregnancy: contraindicated; enforce effective contraception for women of childbearing potential. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors without dose modification. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lenalidomide may interact with several medication classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase drug exposure. - Live vaccines: risk of uncontrolled infection due to immunosuppression. - Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - P‑glycoprotein inhibitors (e.g., verapamil): modestly raise plasma levels. - Other immunomodulatory agents (e.g., thalidomide, pomalidomide): additive toxicity potential.